WHAT IS CLAIMED IS:

1. A biopharmaceutical flow port comprising:

a hose barb comprising a bore; and

an elliptic body comprising a first end and a second end opposite the first end, the second end of the elliptical body coupled to the hose barb, the elliptic body comprising:

an inlet on the first end of the elliptical body and an outlet on the second end of the elliptical body; and

a flow passage that extends from the inlet to the outlet, the outlet fluidly coupled to the bore, the flow passage at least partially defined by:

a first flow passage portion comprising a first cross-section, the first flow passage portion extending a length of the elliptical body from the first end to the second end; and

a second flow passage portion coupled to the first flow passage portion, the second flow passage portion comprising a second cross-section different than the first cross-section, the second flow passage portion superimposed on the first flow passage portion and extending the length of the elliptical body from the first end to the second end, the flow passage configured to pass fluid through the elliptical body from the inlet through both the first flow passage portion and the second flow passage portion to the outlet of the flow passage;

a first edge that extends from the elliptic body away from the flow passage in a first direction; and

a second edge that extends from the elliptic body away from the flow passage in a second direction opposite the first direction.

2. The biopharmaceutical flow port of claim 1, wherein the hose barb is integrally formed with the elliptic body.

3. The biopharmaceutical flow port of claim 1, wherein the hose barb comprises a ridge configured to secure a conduit into fluid communication with the bore.

4. The biopharmaceutical flow port of claim 1, wherein the flow passage is defined at least partially by:

the first cross-section of the first flow passage portion comprising an elliptical cross-section; and

the first cross-section of the second flow passage portion comprising a circular cross-section.

5. The biopharmaceutical flow port of claim 4, wherein the first flow passage portion and the second flow passage portion are fluidly coupled.

6. The biopharmaceutical flow port of claim 4, wherein a radial centerline of the bore coincides with a radial centerline of the second flow passage portion.

7. The biopharmaceutical flow port of claim 4, wherein the second flow passage portion meets the bore at a rounded shoulder of an inner surface of the elliptic body defined by the flow passage.

8. The biopharmaceutical flow port of claim 7, wherein the flow passage comprises a frusto-conical inner surface portion of the elliptic body, the frusto-conical inner surface portion comprising a transition from the flow passage to the bore.

9. The biopharmaceutical flow port of claim 1, wherein the first flow passage portion is concentric within the second flow passage portion.

10. The biopharmaceutical flow port of claim 12, wherein:

a diameter of the circular cross-section and a diameter of the bore are substantially equal,

a radial centerline of the bore coincides with a radial centerline of the flow passage, and

the flow passage meets the bore at a rounded shoulder of an inner surface of the elliptic body defined by the flow passage.

11. The biopharmaceutical flow port of claim 10, wherein the flow passage comprises a frusto-conical inner surface portion of the elliptic body, the frusto-conical inner surface portion comprising a transition from the flow passage to the bore.

12. The biopharmaceutical flow port of claim 1,

the first cross-section of the first flow passage portion comprises a rounded rectangular cross-section; and

the first cross-section of the second flow passage portion comprises a circular cross-section.

13. The biopharmaceutical flow port of claim 12, wherein the first flow passage portion and the second flow passage portion are fluidly coupled.

14. The biopharmaceutical flow port of claim 13, wherein a radial centerline of the bore coincides with a radial centerline of the second flow passage portion.

15. The biopharmaceutical flow port of claim 13, wherein the second flow passage portion meets the bore at a rounded shoulder of an inner surface of the elliptic body defined by the flow passage.

16. The biopharmaceutical flow port of claim 15, wherein a major dimension and a minor dimension of the rounded rectangular cross-section decrease from a first end of the elliptic body to a second end of the elliptic body, the second end of the elliptic body closer to the hose barb than the first end.

17. The biopharmaceutical flow port of claim 16, wherein an inner surface of the elliptic body comprises a transition from the flow passage to the bore.

18. The biopharmaceutical flow port of claim 12, wherein:

the bore and the second flow passage portion comprise a contiguous opening,

the second flow passage portion extends through the first flow passage portion into the hose barb, and

the circular cross-section extends outside the rounded rectangular cross-section.

19. The biopharmaceutical flow port of claim 1, further comprising a ribbed portion formed on an outer surface of the elliptic body, and the ribbed portion extends across the outer surface of the elliptic body from each of the first and second edges toward the hose barb.

20. The biopharmaceutical flow port of claim 1, wherein the first edge and the second edge are integrally formed with the elliptic body, and each of the first and second edges comprises a first curved surface and a second curved surface that mirrors the first curved surface and meets the first curved surface at an edge.

21. The biopharmaceutical flow port of claim 1, wherein the bore is defined by a first radial dimension at a first end near the elliptic body and a second radial dimension larger than the first radial dimension at a second end opposite the first end.

22. The biopharmaceutical flow port of claim 1, further comprising tabs that extend from the elliptic body.

23. The biopharmaceutical flow port of claim 1, wherein the first flow passage portion and the second flow passage portion are of substantially equal length.